ProPhase Labs, Inc. Taxes Payable, Current
ProPhase Labs, Inc. (PRPH) had Taxes Payable, Current of $791.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:TaxesPayableCurrent · last filed 2026-08-19
- 2026-06-30: Taxes Payable, Current $791.00K.
- 2026-03-31: Taxes Payable, Current $793.00K.
- 2025-12-31: Taxes Payable, Current $281.00K.
- 2025-09-30: Taxes Payable, Current $291.00K.
| Period end | Taxes Payable, Current | Taxes Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $791.00K 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $793.00K 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $281.00K 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $291.00K 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $1.37M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.46M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $1.99M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $2.27M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $2.66M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $3.00M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $3.28M 10-K · filed 2025-04-01 | $3.28M 10-K · filed 2024-03-29 |
| 2023-09-30 | $3.31M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.39M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $3.85M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $4.19M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $8.34M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $6.79M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $4.29M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $1.31M 10-K · filed 2023-03-29 | |
| 2019-06-30 | $2.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $3.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $106.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $2.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $740.00K 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $740.00K 10-Q/A · filed 2018-08-20 | $6.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $740.00K 10-K · filed 2019-03-26 | $18.00K 10-Q · filed 2018-05-15 |
| 2017-09-30 | $751.00K 10-Q/A · filed 2018-08-20 | |
| 2017-06-30 | $751.00K 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | $2.09M 10-Q/A · filed 2018-08-20 | $1.34M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |